Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
If your ulcerative colitis is still flaring, your colon may not be healing because therapy is not strong enough, mucosal healing is incomplete despite fewer symptoms, steroid dependence persists, or treatment escalation has been delayed, all of which can raise long-term risks.
There are several factors to consider. If you are biologic naive, you may be eligible for closely monitored clinical trials offering access to new biologics or oral small molecules and precision strategies that could change your next steps; see the complete guidance below for how to confirm active inflammation, assess eligibility, and know when urgent care is needed.
If you're living with ulcerative colitis (UC) and still dealing with flares, bleeding, urgency, or fatigue despite treatment, you're not alone. Many people expect symptoms to settle quickly once they start medication. But sometimes, the colon doesn't heal the way we hope.
Understanding why your UC is still active—and what new options may be available, including clinical trials for biologic-naive UC—can help you take the next step with confidence.
Ulcerative colitis is a chronic autoimmune disease. Your immune system mistakenly attacks the lining of your colon, causing inflammation and ulcers. Healing takes more than symptom control—it requires calming the immune response deep inside the tissue.
Here are some common reasons flares continue:
Mild-to-moderate UC is often treated with:
These can work well for some people. But if inflammation is moderate to severe, they may not be enough to fully suppress the immune attack.
You may feel "better," but ongoing microscopic inflammation can persist. Studies show that true healing of the colon lining—called mucosal healing—is linked to:
If inflammation continues silently, flares often return.
Steroids can reduce symptoms quickly, but they are not a long-term solution. If symptoms return every time steroids are tapered, it's a sign that the underlying disease is still active.
Sometimes there is hesitation to "step up" treatment. But untreated inflammation can cause:
Early control of inflammation is increasingly recommended in modern treatment guidelines.
If you have never been treated with biologic medications, you are considered biologic-naive.
Biologics are advanced therapies that target specific parts of the immune system. Examples include medications that block:
Biologics are often used in moderate-to-severe UC, especially when other medications fail or are not tolerated.
Being biologic-naive can matter. Research shows that patients who start biologics earlier—before cycling through multiple therapies—may respond better in some cases.
If you are still flaring and have not yet started a biologic, you may qualify for clinical trials for biologic-naive UC.
Clinical trials are carefully designed research studies that evaluate:
They follow strict safety and ethical standards and are monitored closely.
Participating in clinical trials for biologic-naive UC may offer:
For some patients, clinical trials provide an option when standard treatments have not worked—or when they want to explore alternatives early in their disease course.
Modern UC research is focused on precision medicine—matching the right drug to the right patient.
Emerging therapies in clinical trials for biologic-naive UC include:
These are more targeted and may:
Unlike biologics (which are injections or infusions), small molecules are pills. Some target:
They act inside immune cells to interrupt inflammation.
Some newer drugs are designed to work mainly in the digestive tract, which may reduce whole-body side effects.
Research is also exploring:
The goal is long-term remission—not just temporary symptom relief.
You may want to speak with your gastroenterologist about new options or clinical trials for biologic-naive UC if:
Early, aggressive control of inflammation can change the long-term course of disease. This is not about overtreatment—it's about preventing complications.
It's important to be honest: uncontrolled UC carries real risks.
Long-term inflammation can increase:
That said, many patients achieve deep remission with the right therapy. The key is finding what works for you.
Clinical trials are not just for "last resort" cases. Many studies specifically recruit biologic-naive patients because researchers want to understand how new therapies perform earlier in the disease process.
Before enrolling, consider:
Ask your doctor detailed questions. Clinical research teams are required to explain risks and benefits clearly.
Sometimes symptoms can overlap with:
If you're experiencing new or worsening symptoms and want to better understand what might be causing them, try Ubie's free AI-powered Ulcerative Colitis symptom checker to help identify whether your concerns could be related to active inflammation—giving you a clearer picture before your next doctor's appointment.
If your UC is still flaring, consider:
You deserve a treatment plan aimed at remission—not just symptom control.
Speak to a doctor immediately or seek emergency care if you experience:
These can signal serious complications.
If your colon isn't healing, it's not a personal failure—and it doesn't mean you're out of options.
Ulcerative colitis treatment has advanced significantly in recent years. For those who have never tried biologics, clinical trials for biologic-naive UC may offer access to promising new therapies and closer medical supervision.
The goal today is not just managing flares. It's achieving deep remission, protecting your colon, and improving long-term health.
If you're still flaring, now is the time to have a direct conversation with your gastroenterologist. Ask about objective testing, treatment escalation, and whether you qualify for clinical trials for biologic-naive UC.
And most importantly, speak to a doctor about any symptoms that could be serious or life-threatening. Early action can make a meaningful difference in your outcome—and your quality of life.
(References)
* Wang Y, Zhao C, Sun J, Feng H. Biomarkers in Ulcerative Colitis: Towards a Personalized Therapeutic Approach for Mucosal Healing. J Inflamm Res. 2023 Sep 26;16:4023-4040. doi: 10.2147/JIR.S426639. PMID: 37780829; PMCID: PMC10540454.
* Kim Y, Koo JS, Lee H. Management of refractory ulcerative colitis. J Int Med Res. 2022 Oct;50(10):3000605221133373. doi: 10.1177/03000605221133373. PMID: 36248386; PMCID: PMC9603091.
* D'Souza S, Allegretti JR. Emerging Therapies in Ulcerative Colitis: Optimizing Treatment for Biologic-Naive Patients. Gastroenterol Clin North Am. 2023 Sep;52(3):477-495. doi: 10.1016/j.gtc.2023.05.006. PMID: 37549887.
* D'Haens G, Loftus EV Jr, Panés J, Singh S, Agrawal N, Bopanna S, Sandborn WJ. Upadacitinib as a treatment for patients with moderately to severely active ulcerative colitis who are naive to biologics: a post-hoc analysis of the U-ACCOMPLISH and U-ACHIEVE clinical trials. Lancet Gastroenterol Hepatol. 2023 Oct;8(10):901-912. doi: 10.1016/S2468-1253(23)00155-7. PMID: 37599021.
* Khan H, Asim M, Alqahtani A, Aldalbahi A, Al-Malki B, Alqazlan R, Alfadli H. Emerging Small Molecule and Biologic Therapies for Ulcerative Colitis: A Review. Int J Mol Sci. 2023 Jan 22;24(3):2223. doi: 10.3390/ijms24032223. PMID: 36768379; PMCID: PMC9917325.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.